A recent clinical trial published in Nature Medicine has sparked significant interest and skepticism within the oncology community. The study reported that lung cancer patients receiving immunotherapy infusions in the morning experienced a substantial reduction in progression risk compared to those treated in the afternoon. This finding has raised hopes for optimizing treatment schedules, yet many experts remain cautious about its validity.
In response to growing concerns, Nature Medicine has announced an investigation into the study’s methodology and data integrity. Critics have highlighted discrepancies in the trial’s design, including inconsistencies on its clinicaltrials.gov registration page and chronological errors in the submitted protocol. Additionally, questions have arisen regarding the reported progression-free survival and adverse event data. While the study authors have refrained from commenting, they are reportedly preparing a response to the journal. This scrutiny underscores the critical importance of rigorous data validation in clinical research, particularly in the high-stakes field of oncology.
Open the full market picture for your next decision →
